Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ther Clin Risk Manag. 2007 Dec;3(6):1165-73.

Update on the treatment of disseminated fusariosis: Focus on voriconazole.

Author information

  • 1Institute of Haematology and Clinical Oncology “Ariosto e Lorenzo Seràgnoli”, S. Orsola-Malpighi Hospital, University of Bologna, Italy. marta.stanzani2@unibo.it

Abstract

Invasive fungal infections are a major cause of morbidity and mortality in immunocompromised patients, such as subjects with hematological malignancies and patients who underwent to hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT). Fusarium spp. cause a broad spectrum of infections in humans. Immunologically competent hosts show mainly localized skin infections, whereas disseminated fusariosis occurs almost exclusively in immunocompromised patients. Fusarium spp. are resistant to many antifungal agents with equivocal in vitro and in vivo susceptibility to amphotericin B. Voriconazole (VRC) is a triazole shown to be safe, well tolerated, and in vitro efficacious against Fusarium spp. Although clinical experience is limited, many case reports have shown the efficacy of VRC in the treatment of fusariosis.

KEYWORDS:

aspergillus; cancer; fungal infections; fusariosis; immunocompromised patient; voriconazole

PMID:
18516266
[PubMed]
PMCID:
PMC2387295
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk